IOVA: Iovance Biotherapeutics, Inc.
About
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Current Value
$8.211 Year Return
Current Value
$8.211 Year Return
Key Details
Market Cap
$2.50B
P/E Ratio
-5.48
1Y Stock Return
58.41%
1Y Revenue Growth
12751.20%
Dividend Yield
0.00%
Price to Book
3.2
Strategies that include IOVA
Stock's related to IOVA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AWI | 47.84% | $6.69B | +84.16% | 0.75% |
| VTYX | 44.49% | $125.87M | -23.61% | 0.00% |
| CRSP | 44.44% | $4.01B | -30.49% | 0.00% |
| THRM | 44.28% | $1.28B | -10.01% | 0.00% |
| DIOD | 42.67% | $2.53B | -20.36% | 0.00% |
| PK | 39.65% | $2.95B | -0.49% | 11.79% |
| HCKT | 39.65% | $838.57M | +36.65% | 1.45% |
| BEAM | 39.39% | $2.09B | -9.52% | 0.00% |
| AKRO | 39.12% | $2.17B | +93.09% | 0.00% |
| KN | 37.97% | $1.60B | +12.19% | 0.00% |
| OPEN | 37.17% | $1.14B | -31.62% | 0.00% |
| AKAM | 37.01% | $13.12B | -22.78% | 0.00% |
| TNL | 36.79% | $3.60B | +42.43% | 3.72% |
| EVH | 36.69% | $1.39B | -58.46% | 0.00% |
| CRBU | 36.45% | $180.20M | -62.45% | 0.00% |
| ASTH | 36.45% | $2.01B | +24.82% | 0.00% |
| RICK | 36.33% | $440.11M | -13.68% | 0.51% |
| KFRC | 36.27% | $1.10B | -8.71% | 0.66% |
| ENOV | 36.26% | $2.53B | -10.59% | 0.00% |
| PATK | 36.16% | $2.90B | +54.53% | 1.67% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MMC | -0.12% | $108.41B | +10.89% | 1.37% |
| VHC | -0.19% | $19.06M | -38.36% | 0.00% |
| LMT | 0.19% | $126.40B | +18.99% | 2.36% |
| PG | 0.20% | $402.15B | +14.14% | 2.33% |
| MITK | -0.25% | $401.51M | -22.13% | 0.00% |
| CME | -0.27% | $82.76B | +9.21% | 1.98% |
| TXO | 0.28% | $737.26M | -1.80% | 13.22% |
| SYPR | -0.31% | $32.23M | -26.32% | 0.00% |
| SOC | 0.32% | $1.93B | +74.70% | 0.00% |
| MANU | -0.42% | $2.88B | -9.41% | 0.00% |
| ASPS | 0.47% | $22.36M | -80.26% | 0.00% |
| VRSK | -0.50% | $39.77B | +17.45% | 0.53% |
| INSG | 0.56% | $157.28M | +540.25% | 0.00% |
| KRRO | 0.60% | $436.84M | +20.68% | 0.00% |
| ZCMD | 0.61% | $2.80M | -88.67% | 0.00% |
| SRRK | 0.64% | $2.61B | +134.91% | 0.00% |
| WHLM | 0.73% | $17.64M | -29.34% | 0.00% |
| GL | 0.78% | $9.18B | -8.60% | 0.86% |
| BROS | -0.85% | $5.67B | +74.77% | 0.00% |
| FTNT | 0.86% | $69.59B | +72.67% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -13.70% | $78.15B | +35.51% | 0.42% |
| MNOV | -13.24% | $93.19M | +2.15% | 0.00% |
| BTCT | -12.53% | $42.61M | +353.33% | 0.00% |
| HUSA | -12.30% | $16.69M | -11.56% | 0.00% |
| LITB | -10.80% | $35.48M | -75.45% | 0.00% |
| PRPO | -10.04% | $9.10M | -13.65% | 0.00% |
| COR | -9.29% | $47.48B | +21.20% | 0.86% |
| DOGZ | -8.97% | $614.77M | +1,372.26% | 0.00% |
| TH | -8.52% | $839.02M | -24.49% | 0.00% |
| PANW | -7.35% | $126.99B | +46.98% | 0.00% |
| PGR | -7.08% | $149.10B | +57.29% | 0.45% |
| RNR | -6.74% | $13.74B | +23.09% | 0.58% |
| TCTM | -6.73% | $8.10M | -42.99% | 0.00% |
| ACGL | -6.46% | $36.00B | +16.84% | 0.00% |
| WLKP | -5.98% | $796.39M | +4.00% | 8.34% |
| STG | -5.50% | $35.67M | +7.92% | 0.00% |
| UEIC | -5.27% | $148.52M | +43.22% | 0.00% |
| ALL | -5.23% | $52.06B | +45.67% | 1.85% |
| TPST | -5.19% | $37.75M | -77.59% | 0.00% |
| OXBR | -4.98% | $19.05M | +178.18% | 0.00% |
ETF's related to IOVA
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 50.02% | $6.58B | 0.35% |
| GNOM | 46.75% | $70.59M | 0.5% |
| IBB | 45.54% | $6.66B | 0.45% |
| XPH | 45.02% | $157.87M | 0.35% |
| IVOV | 44.80% | $964.95M | 0.15% |
| FYX | 44.43% | $959.00M | 0.6% |
| VIOO | 44.38% | $3.12B | 0.1% |
| XSMO | 44.31% | $1.25B | 0.39% |
| IJJ | 44.26% | $8.03B | 0.18% |
| GSSC | 44.19% | $529.86M | 0.2% |
| PTH | 44.16% | $143.31M | 0.6% |
| JMEE | 43.94% | $1.51B | 0.24% |
| PBE | 43.91% | $258.53M | 0.58% |
| ISCG | 43.85% | $640.00M | 0.06% |
| ARKG | 43.16% | $1.13B | 0.75% |
| MDYV | 42.91% | $3.25B | 0.15% |
| IJR | 42.90% | $90.05B | 0.06% |
| SMMD | 42.42% | $1.24B | 0.15% |
| IWO | 42.35% | $12.56B | 0.24% |
| VTWO | 42.19% | $12.38B | 0.1% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XHLF | 0.09% | $874.27M | 0.03% |
| SOYB | -0.31% | $27.32M | 0.22% |
| BOXX | -0.45% | $4.43B | 0.1949% |
| KCCA | -1.00% | $220.51M | 0.87% |
| TBIL | 1.19% | $4.38B | 0.15% |
| JBBB | 1.27% | $1.26B | 0.49% |
| DBMF | 1.50% | $1.02B | 0.85% |
| KRBN | 1.89% | $242.47M | 0.85% |
| TPMN | 2.01% | $40.60M | 0.65% |
| CORN | -2.15% | $61.12M | 0.2% |
| CCOR | 2.22% | $109.04M | 1.18% |
| BSCO | 2.56% | $2.35B | 0.1% |
| BILZ | 2.70% | $563.02M | 0.14% |
| XBIL | 2.76% | $637.70M | 0.15% |
| MINT | -2.85% | $11.62B | 0.35% |
| IBHD | 2.94% | $327.80M | 0.35% |
| DBA | 3.07% | $755.88M | 0.93% |
| DBO | 3.18% | $217.57M | 0.77% |
| IBD | -3.32% | $330.68M | 0.44% |
| WEAT | 3.52% | $120.27M | 0.28% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -35.11% | $388.04M | 1.43% |
| VIXY | -23.73% | $195.31M | 0.85% |
| USDU | -21.10% | $201.97M | 0.5% |
| TAIL | -19.39% | $67.98M | 0.59% |
| UUP | -18.06% | $309.25M | 0.77% |
| CTA | -15.94% | $350.27M | 0.78% |
| KMLM | -15.24% | $353.87M | 0.9% |
| EQLS | -9.40% | $76.08M | 1% |
| FMF | -5.75% | $244.61M | 0.95% |
| CLOI | -5.45% | $715.40M | 0.4% |
| JUCY | -5.37% | $324.29M | 0.6% |
| AGZD | -4.90% | $142.76M | 0.23% |
| HIGH | -4.78% | $302.78M | 0.51% |
| HDRO | -4.37% | $164.26M | 0.3% |
| IBD | -3.32% | $330.68M | 0.44% |
| MINT | -2.85% | $11.62B | 0.35% |
| CORN | -2.15% | $61.12M | 0.2% |
| KCCA | -1.00% | $220.51M | 0.87% |
| BOXX | -0.45% | $4.43B | 0.1949% |
| SOYB | -0.31% | $27.32M | 0.22% |
News
Yahoo
Iovance Biotherapeutics ( NASDAQ:IOVA ) Third Quarter 2024 Results Key Financial Results Revenue: US$58.6m (up by...
SeekingAlpha
Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors. See my recommendation on IOVA stock.
Yahoo
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) just released its quarterly report and things are looking bullish...
Yahoo
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
Yahoo
Iovance Biotherapeutics Inc (IOVA) reports strong Q3 2024 revenue, exceeding guidance, while addressing challenges and setting ambitious targets for 2025.
Yahoo
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 9.68% and 9.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.